Neuromyelitis Optica Spectrum Disorder

R&D

A Horizon of hope: UPLIZNA data, NMOSD, and ECTRIMS

Neurological conditions like Multiple Sclerosis (MS) are an incredibly important area of research when it comes to drug discovery, but under that (sometim

News

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Neuromyelitis Optica Spectrum Disorder

Editor's Picks